Willem J. Lesterhuis

35 Stirling Highway
Crawley, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

TIME in motion: How response takes shape.

TIME in motion: How response takes shape.

Journal: Cancer cell

Published: June 11, 2026

A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

Journal: Journal of medicinal chemistry

Published: November 11, 2025

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.

Journal: Scientific reports

Published: November 03, 2025

Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients.

Comparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients.

Journal: Oxford open immunology

Published: December 10, 2024

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade.

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: September 08, 2024

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade.

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade.

Journal: Oncoimmunology

Published: August 27, 2024

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

Journal: Oncoimmunology

Published: April 30, 2024

Exploiting temporal aspects of cancer immunotherapy.

Exploiting temporal aspects of cancer immunotherapy.

Journal: Nature reviews. Cancer

Published: April 25, 2024

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.

The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.

Journal: Frontiers in toxicology

Published: January 19, 2024

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.

Journal: Cell reports. Medicine

Published: December 26, 2023

Protocol for delivery of intraoperative immunotherapy to mice by surgical debulking of subcutaneous tumors.

Protocol for delivery of intraoperative immunotherapy to mice by surgical debulking of subcutaneous tumors.

Journal: STAR protocols

Published: November 16, 2023

Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner.

Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner.

Journal: BMC cancer

Published: August 18, 2023

Showing 1-12 of 60

Last Updated: 09/26/2026